<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03254342</url>
  </required_header>
  <id_info>
    <org_study_id>28162</org_study_id>
    <nct_id>NCT03254342</nct_id>
  </id_info>
  <brief_title>MRS and Medication Response: A Pilot Study</brief_title>
  <official_title>Magnetic Resonance Spectroscopy and Medication Response: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hope to demonstrate that magnetic resonance spectroscopy can detect brain concentration&#xD;
      levels of paroxetine (Paxil) or citalopram (Celexa) or escitalopram (Lexapro) in depressed&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to demonstrate that it is feasible to image paroxetine&#xD;
      (Paxil) or citalopram (Celexa) or escitalopram (Lexapro) brain concentrations using MRS&#xD;
      technology in depressed patients.&#xD;
&#xD;
      The longer-term goal is to determine the relationship between clinically administered doses&#xD;
      of paroxetine (Paxil) or citalopram (Celexa) or escitalopram (Lexapro) (antidepressants), the&#xD;
      amount of drug in the body via blood level, the concentrations of the drug achieved in brain&#xD;
      measured via MRS, and genetics.&#xD;
&#xD;
      It has been previously reported that individuals taking 20mg of paroxetine daily had brain&#xD;
      paroxetine [(Paxil) levels via MRS ranging from 2-13 micromolar. Similar or slightly higher&#xD;
      ranges of brain drug concentrations have been reported for fluoxetine and fluvoxamine.&#xD;
&#xD;
      Since not all depressed patients respond to medications, one reason may be the amount of&#xD;
      medication that crosses the blood-brain barrier. This may be influenced by genetic&#xD;
      information. We want to examine these issues on a larger scale, but first we need to&#xD;
      demonstrate that we can indeed determine paroxetine [(Paxil) or citalopram (Celexa) or&#xD;
      escitalopram (Lexapro)] levels via MRS.&#xD;
&#xD;
      Intended results analysis could not be conducted because a reliably sensitive spectroscopic&#xD;
      method could not be developed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to obtain a reliable MRS signal&#xD;
  </why_stopped>
  <start_date type="Actual">August 6, 2013</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">August 6, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of paroxetine (Paxil), citalopram (Celexa) or escitalopram (Lexapro) brain concentrations.</measure>
    <time_frame>Within 7 Days following MRS</time_frame>
    <description>Measurement of paroxetine (Paxil), citalopram (Celexa) or escitalopram (Lexapro) brain concentrations using MRS technology in depressed participants.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">3</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Major Depressive Episode</condition>
  <condition>Major Depressive Disorder, Recurrent</condition>
  <condition>Major Depression Mild</condition>
  <condition>Major Depression Moderate</condition>
  <condition>Major Depression Severe</condition>
  <arm_group>
    <arm_group_label>Major depressive disorder</arm_group_label>
    <description>There is no intervention/treatment in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-depressed individuals</arm_group_label>
    <description>There is no intervention/treatment in this study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Psychiatry clinic; local community.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Major depressive disorder:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. DSM diagnosis of Major Depressive Disorder&#xD;
&#xD;
          2. Taking paroxetine [(Paxil) or citalopram (Celexa) or escitalopram (Lexapro)]for at&#xD;
             least 6 weeks&#xD;
&#xD;
          3. Between 21 - 75 years of age.&#xD;
&#xD;
          4. Taking a stable dose of paroxetine [(Paxil) or citalopram (Celexa) or escitalopram&#xD;
             (Lexapro)] for at least the 2 weeks prior to the imaging session&#xD;
&#xD;
        Healthy controls:&#xD;
&#xD;
          1. Between 21 - 75 years of age.&#xD;
&#xD;
          2. Have a 21-item HAM-D score of less than or equal to 5.&#xD;
&#xD;
          3. No current, or history of any Axis I disorder.&#xD;
&#xD;
        Identify exclusion criteria.&#xD;
&#xD;
        Exclusion criteria are as follows:&#xD;
&#xD;
          1. Contraindications for an MRI exam. These includes biomedical devices such as&#xD;
             pacemakers, aneurysm clips, prostheses, and other metallic objects embedded in the&#xD;
             body such as bullets, buckshot, shrapnel, and any metal fragments from working around&#xD;
             metal.&#xD;
&#xD;
          2. Current pregnancy or lactation.&#xD;
&#xD;
          3. Patients with claustrophobia.&#xD;
&#xD;
          4. History, or current Axis I or Axis II disorders&#xD;
&#xD;
          5. Active unstable medical problems, as confirmed by screening procedures&#xD;
&#xD;
          6. Diagnosed with any autoimmune disease, (e.g., rheumatoid arthritis, Lupus, MLS).&#xD;
&#xD;
          7. Chronic use of steroids or opiates.&#xD;
&#xD;
          8. Positive urine toxicology screen for illicit substances of abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University Psychiatry and Biobehavioral Sciences</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2017</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Alan Schatzberg</investigator_full_name>
    <investigator_title>Professor, Department of Psychiatry and Behavioral Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Currently there is no plan.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

